Cover Image
市場調查報告書

全球慢性阻塞性肺病(COPD)市場

Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 315302
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
全球慢性阻塞性肺病(COPD)市場 Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018
出版日期: 2014年10月01日 內容資訊: 英文 79 Pages
簡介

慢性阻塞性肺病(COPD),廣義是指肺氣腫、慢性支氣管炎、難治性氣喘、支氣管擴張症等各種進行性肺部疾病。慢性阻塞性肺病的病因雖無法確定,不過遺傳要素和大氣污染等為一部分原因。現狀是,這個疾病無法痊癒,對症療法成為主要的治療方法。全球慢性阻塞性肺病,預計從2013年到2018年,以5.69%的年複合成長率擴大。

本報告提供全球慢性阻塞性肺病(COPD)的現狀與目前趨勢、各治療類型及地區趨勢、市場成長要素和課題、主要企業分析等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測

第7章 慢性阻塞性肺病的管理

  • 波特的五力分析

第8章 各治療類型的市場區隔

第9章 地理區隔

  • 南北美洲的慢性阻塞性肺病市場
  • 歐洲、中東、非洲市區的慢性阻塞性肺病市場
  • 亞太地區的慢性阻塞性肺病市場

第10章 購買標準

第11章 罹患率和得病率

  • 美國
  • 歐洲
  • 亞太地區

第12章 開發平台概要

第13章 市場成長因素

第14章 成長因素與其影響

第15章 市場課題

第16章 成長因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第20章 主要供應商分析

  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Pfizer Inc.

第21章 相關報告

目錄
Product Code: IRTNTR4201

About COPD

COPD is a broad term that covers various progressive lung diseases including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It is a serious condition that restricts airflow in the lungs and is characterized by increasing breathlessness. The exact etiology of COPD is not understood; however, most cases of COPD are caused due to genetic factors and by inhaling pollutants, including fumes and chemicals. The disease cannot be cured; it can be only be managed and treated.

TechNavio's analysts forecast the Global COPD market to grow at a CAGR of 5.69 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global COPD market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs in the form of oral medications as well as inhalers for the treatment of COPD. The Global COPD market can be segmented into five: Medications, Oxygen Therapy, Surgery, Pulmonary Rehabilitation, and Lifestyle Changes.

TechNavio's report, the Global COPD Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global COPD market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Astra Zeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Alere
  • Almirall
  • Astellas Pharma
  • Axis Shield
  • Beckton Dckinson
  • Biosensors International
  • Dainippon Sumitomo Pharma
  • Medtronic
  • Merck
  • Mylan
  • Novartis
  • Siemens Healthcare Diagnostics
  • Takeda Pharmaceutical
  • Theravance

Market Driver

  • Elderly Population

For a full, detailed list, view our report

Market Challenge

  • High Cost of COPD Treatment

For a full, detailed list, view our report

Market Trend

  • Increase in Awareness of COPD

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast

07. Management of COPD

  • 07.1. Five Forces Analysis

08. Market Segmentation by Type of Treatment

09. Geographical Segmentation

  • 09.1. COPD Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. COPD Market in the EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. COPD Market in the APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Rate of Incidence and Prevalence

  • 11.1.1. US
  • 11.1.2. Europe
  • 11.1.3. Asia

12. Pipeline Snapshot

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. AstraZeneca plc
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Business Segmentation
    • 20.1.4. Business Strategy
    • 20.1.5. Revenue by Business Segmentation
    • 20.1.6. Revenue Comparison 2011-2013
    • 20.1.7. Sales Revenue by Geographical Segmentation
    • 20.1.8. Key Developments
    • 20.1.9. SWOT Analysis
  • 20.2. Boehringer Ingelheim
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation by Revenue 2013
    • 20.2.4. Business Segmentation by Revenue 2012 and 2013
    • 20.2.5. Geographical Segmentation by Revenue 2013
    • 20.2.6. Business Strategy
    • 20.2.7. Recent Developments
    • 20.2.8. SWOT Analysis
  • 20.3. GlaxoSmithKline plc
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation
    • 20.3.4. Business Segmentation by Revenue 2012 and 2013
    • 20.3.5. Sales by Geography
    • 20.3.6. Pipeline Products
    • 20.3.7. Business Strategy
    • 20.3.8. Key Information
    • 20.3.9. SWOT Analysis
  • 20.4. Pfizer Inc.
    • 20.4.1. Key Facts
    • 20.4.2. Business Description
    • 20.4.3. Business Segmentation
    • 20.4.4. Revenue by Business Segmentation
    • 20.4.5. Revenue Comparison 2012 and 2013
    • 20.4.6. Sales by Geography
    • 20.4.7. Business Strategy
    • 20.4.8. Key Developments
  • 20.5. SWOT Analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1:Market Research Methodology
  • Exhibit 2:Global COPD Market 2013-2018 (US$ billion)
  • Exhibit 3:Global COPD Market Segmentation by Type of Treatment
  • Exhibit 4:Global COPD Market Segmentation by Drug Class
  • Exhibit 5:Global COPD Market Segmentation by Drug Class 2013
  • Exhibit 6:Global COPD Market by Geographical Segmentation 2013
  • Exhibit 7:COPD Market in Americas 2013-2018 (US$ billion)
  • Exhibit 8:COPD Market in the EMEA Region
  • Exhibit 9:COPD Market in the APAC Region
  • Exhibit 10:Global COPD Market by Geographical Segmentation 2013-2018 (in percent)
  • Exhibit 11:Global COPD Market by Geographical Segmentation 2013-2018 (in revenue)
  • Exhibit 12:AstraZeneca plc: Business Segmentation
  • Exhibit 13:AstraZeneca plc: Revenue by Business Segmentation2013
  • Exhibit 14:AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 15:AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 16:Boehringer Ingelheim: Business Segmentation by Revenue 2013
  • Exhibit 17:Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18:Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
  • Exhibit 19:GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 20:GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 21:GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 22:GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 23:Pfizer Inc.: Business Segmentation
  • Exhibit 24:Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 25:Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 26:Pfizer Inc.: Revenue by Geography 2013
Back to Top